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The placenta is a transient organ essential for fetal development. During human placental development, chorionic villi grow in
coordination with a large capillary network resulting from both vasculogenesis and angiogenesis. Angiogenin is one of the most
potent inducers of neovascularisation in experimentalmodels in vivo.We andothers have previouslymapped angiogenin expression
in the human term placenta. Here, we explored angiogenin involvement in early human placental development. We studied,
angiogenin expression by in situ hybridisation and/or by RT-PCR in tissues and primary cultured trophoblastic cells and angiogenin
cellular distribution by coimmunolabelling with cell markers: CD31 (PECAM-1), vascular endothelial cadherin (VE-cadherin),
vascular endothelial growth factor receptor-2 (VEGF-R2), Tie-2, von Willebrand factor, CD34, erythropoeitin receptor (Epo-R),
alpha-smooth muscle actin, CD45, cytokeratin 7, and Ki-67. Extravillous and villous cytotrophoblasts, isolated and differentiated
in vitro, expressed and secreted angiogenin. Angiogenin was detected in villous trophoblastic layers, and structured and nascent
fetal vessels. In decidua, it was expressed by glandular epithelial cells, vascular cells and macrophages. The observed pattern of
angiogenin expression is compatible with a role in blood vessel formation and in cross-talk between trophoblasts and endothelial
cells. In view of angiogenin properties, we suggest that angiogenin may participate in placental vasculogenesis and organogenesis.
1. Introduction
The placenta is a transient organ essential for fetal develop-
ment. It acts as an interface between the fetal and maternal
blood circulation, ensuring (1) oxygen and nutrient transfer
and waste removal, (2) immune protection and maternal
tolerance of the semiallogeneic fetus, and (3) endocrine
functions ([1, 2], for reviews). Chorionic villi are the essential
structural and functional components of the human placenta
(schematic representation in Figure 1). Their mesenchymal
core is covered by a two-layered trophoblast epithelium that
rests on a basement membrane in contact with the stromal
core. This trophoblast layer is composed of villous cytotro-
phoblasts that proliferate and differentiate by fusion, forming
a multinucleated syncytiotrophoblast that covers the entire
surface of the villus, in direct contact with a maternal blood
exudate during the first trimester of pregnancy and with
maternal whole blood thereafter. The syncytiotrophoblast
plays a major role in fetomaternal exchanges throughout
pregnancy and in synthesis of steroid and peptide hormones
required for fetal growth and development. A subset of
chorionic villi anchors the placenta to the uterine wall.
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Figure 1: Schematic representation of an anchoring villus from amidgestational placental section, attached to the basal plate by a cell column
(a). Schematic representation of a first-trimester mesenchymal villus: sagittal section (b) and cross-section (c). AV: anchoring villus; BM:
basement membrane; CT: cytotrophoblast; eEVT, iEVT, and pEVT: endovascular-, interstitial-, and proliferating- extravillous trophoblast,
respectively; fc: fetal capillary, HC: Hofbauer cell (macrophage); IS: intervillous space; MC: mesenchymal cell; ST, syncytiotrophoblast; TB:
trophoblast layer; and UPA: uteroplacental artery.
The base of these villi contains proliferating extravillous
cytotrophoblasts aggregated in columns (Figure 1(a)). During
the first and second trimesters, highly invasive extravillous
cytotrophoblasts stop proliferating and invade the uterine
interstitium, while maternal spiral arteries are remodelled
into uteroplacental arteries. The maternal arterial endothe-
lium, unlike the venous endothelium, is replaced by extravil-
lous cytotrophoblasts which adopt an endothelial phenotype
[3, 4]. This endo- and perivascular trophoblast invasion and
arterial remodelling ensures optimal exchanges between the
maternal and fetal circulation.
Angiogenin [5] is one of the most potent inducers of
neovascularization in experimental models in vivo ([6, 7], for
reviews). Its expression is developmentally regulated in rats
and humans [8, 9].We and others have previously shown that
the secreted 14 kDa protein is expressed by placental cells in
the human term placenta, including vascular, trophoblastic,
and amnionic cells [10, 11]. Here, we further probed the
role of angiogenin in placental development. Indeed, early
placental villi start to develop as mesenchymal villi at week
5 of gestation, with fetal capillary segments being formed
by vasculogenesis. These villi develop into immature inter-
mediate villi from week 7 to 8. The capillary segments then
fuse and elongate to form a simple capillary network. Starting
at week 9, the preexisting capillary network expands by
vasculogenesis and branching angiogenesis [12–16]. Decidual
sections provide access to the maternal environment, site
of intense morphological, physiological and immunological
reorganizations. In this work, we examined the distribution
and cellular sources of angiogenin in early human placental
tissues and maternal decidua. Angiogenin transcripts were
detected by in situ hybridisation in tissues and by RT-PCR
in both tissues and primary cultures of villous trophoblasts.
The protein was localized by immunofluorescence from 7.5-
to 9-week placental cryosections, and its cellular distribution
was established by dual immunolabeling with markers for
trophoblastic, epithelial, mesenchymal, and endothelial cells;
vascular smooth muscle cells; endothelial, hematopoietic,
and erythroid precursors; leukocytes and mature monocytes;
and proliferating cells. Angiogenin expression was also stud-
ied in primary cultures of first-trimester extravillous and
villous trophoblasts. We interpreted our findings in view of
recent knowledge of the biological activities of angiogenin.
2. Materials and Methods
2.1. Reagents. Aprotinin, DNase I, ovalbumin, and Triton
X-100 were from Sigma Chemical Co. (St. Louis, MO).
Tween 20 was from Merck (Darmstadt, Germany). Percoll
was from Amersham Pharmacia (Uppsala, Sweden). Culture
media, Hanks buffered saline solution (HBSS), and Hepes
were from Gibco Laboratories (Grand Island, NY). Trypsin
was from Difco Laboratories (Detroit, MI), and penicillin
and streptomycin were from Invitrogen (Illkirch, France).
Fetal bovine serum (FBS) was from Biological Industries
(Kibbutz Beit Haemek, Israel) or PAA Laboratories GmbH
(Les Mureaux, France). Sera were heat-inactivated before
use. Paraformaldehyde (PFA) was from Electron Microscopy
Sciences (Washington, PA). Antibodies used in the study are
listed in Table 1. Normal serum from donkey or goat, human
IgG, and IgG- and protease-free bovine serumalbumin (BSA)
were from Jackson ImmunoResearch (West Grove, PA). All
chemicals were of analytical grade.
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Table 1: Antibodies used in this study.
Antibody specificity Species, isotype Concentrationused Cell specificity in placenta Source
Angiogenin
Rabbit IgG
Mouse IgM
Clone MANG-1
6 𝜇g/mL
6 𝜇g/mL Aim of the study
[10]
Bachem (San Carlos, CA)
Cytokeratin 7 Mouse IgG1Clone OV-TL 12/30 2 𝜇g/mL Trophoblastic cells Dako (Glostrup, Denmark)
Pan cytokeratin
(5, 6, 8, 17, and probably 19)
Mouse IgG1
Clone MNF116 0.9 𝜇g/mL
Epithelial glandular cells
Trophoblastic cells Dako
Vimentin Mouse IgG1Clone V9 5 𝜇g/mL
Endothelial cells,
mesenchymal cells, and
vascular smooth muscle
cells
Monocytes
Macrophages
Immunotech (Marseille,
France)
Alpha smooth muscle actin Mouse IgG2aClone 1A4
Ascites fluid
1/300
Vascular smooth muscle
cells
Sigma ImmunoChemicals
(St. Louis, MO)
Ki-67 Mouse IgG1Clone MIB-1 4 𝜇g/mL Proliferating cells Immunotech
CD31, PECAM-1
(Platelet/endothelial cell
adhesion molecule-1 )
Mouse IgG1
Clone JC/70A 4 𝜇g/mL Endothelial cells Dako
CD34 Mouse IgG1Clone Qbend 10 4 𝜇g/mL
Endothelial cells
Hematopoietic precursors Immunotech
Tie-2
(Tyrosine kinase with
immunoglobulin and
epidermal growth factor
homology domains-2)
Rabbit IgG 6 𝜇g/mL Endothelial cells Santa Cruz Biotechnology(Santa Cruz, CA)
VE-cadherin
(Vascular endothelial
cadherin),
CD144, cadherin 5
Mouse IgG1
Clone TEA1/31 4 𝜇g/mL Endothelial cells Immunotech
VEGF-R2 (Flk-1)
(Vascular endothelial
growth factor receptor-2)
Mouse IgG1
Clone A3 4 𝜇g/mL Endothelial cells Santa Cruz Biotechnology
vWF
(von Willebrand factor) Mouse IgG1 4 𝜇g/mL Endothelial cells
Roche Diagnostics
(Meylan, France)
Epo-R
(Erythropoietin receptor) Rabbit IgG 6 𝜇g/mL
Endothelial cells
Erythroid precursors Santa Cruz Biotechnology
CD14 Mouse IgG2bClone MY4 6 𝜇g/mL
Mature monocytes
Macrophages Immunotech
CD45
(Leukocyte common
antigen)
Mouse IgG1
Clone HI30 6 𝜇g/mL Leukocytes
BD Pharmingen (Le
Pont-de-Claix, France)
Isotype control Mouse IgG1 Nonspecific Coulter Immunology(Hialeah, FL)
Mouse IgG2a Immunotech
Mouse IgG2b Coulter Immunology
Mouse IgM Coulter Immunology
Rabbit IgG
Jackson ImmunoResearch
Laboratories, Inc (West
Grove, PA)
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Table 1: Continued.
Antibody specificity Species, isotype Concentrationused Cell specificity in placenta Source
FITC-conjugated donkey
anti-mouse IgG
Affinity Pure
donkey IgG 3.5 𝜇g/mL Jackson ImmunoResearch
Texas Red-conjugated goat
anti-mouse IgG (subclasses
1 + 2a + 2b + 3)
Affinity Pure goat
IgG, Fc fragment
specific
3.5 𝜇g/mL Jackson ImmunoResearch
FITC-conjugated goat
anti-mouse IgM
Affinity Pure goat
IgG, 𝜇 chain
specific
3.75 𝜇g/mL Jackson ImmunoResearch
FITC-conjugated goat
anti-rabbit IgG
Affinity Pure goat
IgG, Fc fragment
specific
3.75 𝜇g/mL Jackson ImmunoResearch
Rhodamine (TRITC-)
labelled goat anti-rabbit
IgG
Affinity Pure goat
IgG, absorbed
against human IgG
4.4 𝜇g/mL Sigma BioSciences
Texas Red-conjugated
donkey anti-rabbit IgG
Affinity Pure
donkey IgG 3.5 𝜇g/mL Jackson ImmunoResearch
2.2. Tissue Collection. Human placental tissues from first-
trimester pregnancies were collected after legal voluntary
termination (7–14 weeks of gestation) at Broussais and Saint-
Vincent de Paul hospitals (Paris, France). Second-trimester
placentas were collected after medical termination for major
fetal abnormalities [17]. Fetal karyotyping was normal. Term
placentas (>37weeks) were obtained after elective Caesarean
section from healthy mothers with uncomplicated preg-
nancies delivered at Robert Debre´, Saint-Vincent de Paul,
and Tenon hospitals (AP-HP, Paris, France). The study
was approved by our local ethics committee (CCPRB Paris
Cochin no. 18-05) and the patients gave their informed
consent. For immunofluorescence experiments and in situ
hybridisation, pieces of placenta and decidua were embedded
in Tissue-Tek O.C.T Compound (Sakura Finetek Europe,
The Netherlands), frozen in isopentane, cooled with liquid
nitrogen, and stored at −80∘C until cryostat sectioning.
2.3. Villous and Extravillous Trophoblast Isolation and Pri-
mary Culture. Villous placental tissues were dissected free
of membranes and vessels and then rinsed and minced in
Ca++- and Mg++-free HBSS supplemented with 100 IU/mL
penicillin and 100 𝜇g/mL streptomycin. Extravillous cytotro-
phoblasts were isolated by trypsin-DNase digestion as previ-
ously described [18]. Cells were plated on 7𝜇g/cm2Matrigel-
coated dishes in DMEM/10% FBS/2mML-glutamine/25mM
Hepes/100 IU/mL penicillin/100𝜇g/mL streptomycin (5-6 ×
105 cells/2mL/8 cm2 culture dish) and maintained at 37∘C
in humidified 5% CO
2
/95% air (𝑛 = 8). Villous cytotro-
phoblasts were isolated with the method of Kliman et al.
[19], essentially as previously described [20]. Cells were
seeded in HAM F12/DMEM (vol./vol.) containing 10% FBS,
2mM L-glutamine, 100 IU/mL penicillin, and 100 𝜇g/mL
streptomycin (3.3million cells/3mL/20 cm2 culture dish) and
maintained at 37∘C in humidified 5% CO
2
/95% air (𝑛 = 11).
The medium was changed daily for three days. The collected
medium was centrifuged, frozen in liquid nitrogen, and
stored at −20∘C until use. In parallel experiments, cells were
collected for RNA extraction. RT-PCR and ELISA studies
(𝑛 = 3) were performed in triplicate.
2.4. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNA was extracted from frozen placental tis-
sues with TRIzol reagent (Invitrogen SARL, Cergy Pontoise,
France). Total RNA was isolated from cultured cells as
described in the Atlas Pure Total RNA Labeling System
user manual (Clontech Laboratories, Palo Alto, CA). The
total RNA concentration was determined by absorbance at
260 nm and its integrity was checked by 1% agarose gel
electrophoresis in the presence of ethidium bromide withUV
visualisation.
First-strand complementary DNA was synthesised from
2 𝜇g of total RNA using 0.2 𝜇g oligo(dT)
15
as primer
(Promega Co., France) and SuperScript II RNase H Reverse
Transcriptase (Invitrogen SARL) in a 20 𝜇L reaction volume
as per themanufacturer’s instructions.The synthesised cDNA
was then subjected to PCRamplification as described in detail
elsewhere [10]. Gene-specific primers (Table 2) were from
Invitrogen SARL. Negative controls for RT-PCR lacked total
RNA. PolyA+RNA fromhuman liver (Clontech laboratories,
Inc.) was used as a positive control for angiogenin expression.
The absence of contaminating DNA was confirmed by the
obtention of a single RT-PCR product for 𝛽-actin, with the
primers being located in different exons. In order to confirm
that the PCR products are angiogenin amplicon, PCR prod-
ucts from angiogenin cDNA amplification were subjected
to 2% agarose gel electrophoresis, extracted with JETsorb
(GENOMEDGmbH, Germany), cloned in the pCRII-TOPO
plasmid vector (Invitrogen SARL), and sequenced using
the ABI PRISM dRhodamine Terminator Cycle Sequencing
Ready Reaction kit (Perkin Elmer Applied Biosystems).
2.5. In Situ Hybridisation on Placental and Decidual Cryosec-
tions. Angiogenin cDNA (BBG28, R&D systems, Abing-
don, UK) was labelled by incorporation of digoxigenin-
labelled dUTP by random priming with the DIG High Prime
BioMed Research International 5
Table 2: Primer sequences.
Gene GenBank accession number Primer sequences Amplicon length Reference
Human
angiogenin M11567
5󸀠-CAT CAT GAG GAG ACG GGG-3󸀠
sense, bp 1964–1981
264 bp [21]5󸀠-TCC AAG TGG ACA GGT AAG CC-3󸀠
antisense, bp 2227 > 2208
𝛽-actin M10277
5󸀠-ACA ATG AGC TGC GTG TGG CT-3󸀠
sense, bp 1496–1515
371 bp After [22]5󸀠-CTC CTT AAT GTC ACG CAC GAT TTC-3󸀠
antisense, bp 2307 > 2284
Labelling andDetection Kit I according to themanufacturer’s
recommendations (Roche Diagnostics, Meylan, France).
Seven-micrometer-thick frozen sections of placenta or
decidua were mounted on Polysine slides (Menzel-Gla¨ser,
Germany) and thendried andfixedwith 4%PFA for 40min at
4∘C. Remaining free reactive groups were blocked with 0.2%
glycine (w/v). After four washes in PBS, the sections were
dehydrated with graded ethanol solutions (30%, 2 × 50%,
70%, and 2 × 100%), rapidly air-dried, and stored at −80∘C.
After rehydration with graded ethanol solutions (100%, 70%,
and 2 × 50%), the sections were digested with 1 𝜇g/mL
Proteinase K (Sigma) in 20mM Tris-HCl, 1mM EDTA, and
pH 7.6 for 15min at 37∘C. Postfixation was performed with
4% PFA for 20min at 4∘C, followed by blockade of remain-
ing reactive groups with 0.2% glycine (w/v). The sections
were prehybridised at 50∘C for 4 hours in hybridisation
buffer containing 5x standard saline citrate (SSC, Gibco),
0.1% N-lauroylsarcosine (Sigma), 20% blocking solution
(Boehringer kit), 50% deionised formamide (Fluka Chemie,
Buchs, Switzerland), and 0.02% SDS (Bioprobe, Montreuil,
France). Hybridisation was performed overnight at 50∘C in
hybridisation buffer containing 0.25 ng/mL labelled angio-
genin cDNA probe (BBG28). Sections were washed twice in
2x SSC for 5min and twice in 1x SSC for 15min, at 50∘C.
After saturating the sectionswith blocking buffer (Boehringer
kit) for 45min at room temperature, alkaline phosphatase-
conjugated antidigoxigenin Fab (1 : 600) was added for 2
hours. Bound antibodies were revealed overnight by adding
5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro-
blue tetrazolium (NBT) in the presence of 2mM levamisole
to inhibit endogenous alkaline phosphatase activity. After
counterstaining with Mayer’s hematoxylin, the sections were
mounted in Glycergel (Dako SA, Trappes, France). Negative
controls were prepared either by pretreating the sections with
100 𝜇g/mL RNase A for 1 h at 37∘C or by using a nonspecific
digoxigenin-labelled DNA probe (pBR 328).
2.6. Immunoassay. The angiogenin immunoassay was
finalised in our laboratory by using a rabbit polyclonal
anti-angiogenin antibody as previously described [10] with
some modifications. Microtiter plates (Immulon 4 HBX;
Dynatech, Chantilly, France) were coated with 1.8 𝜇g/mL
antiangiogenin IgG diluted in PBS (50𝜇L) overnight at 4∘C.
After three washes with PBS, 0.5‰ Tween 20 (PBS/Tween),
the plates were blocked with 0.1% gelatine, PBS/Tween for
1.5 h at room temperature. Solutions (250𝜇L) containing
either standard or samples buffered with 20mM MOPS, pH
7.2, and diluted if necessary, were distributed and incubated
overnight at 4∘C in a moist chamber. The wells were then
washed three times with PBS/Tween and blocked with 0.1%
gelatine PBS/Tween for 1 h at room temperature. Then, 50𝜇L
of peroxidase-conjugated affinity-purified antiangiogenin
IgG (5 𝜇g/mL in PBS/Tween containing 1% ovalbumin) was
added for 2 h at 37∘C. After three washes with PBS/Tween,
bound antibody was revealed with O-phenylenediamine
dihydrochloride (OPD) and H
2
O
2
; the reaction was
stopped after 5min by adding 4N H
2
SO
4
. Absorbance was
determined at 490 nm in a microplate reader (Dynatech MR
5000). Normal human plasma was used as positive control.
The detection limit was 7.8 pg/mL and the assay range was
7.8–500 pg/mL.
Thehuman chorionic gonadotropin (hCG) concentration
in conditioned media was determined by using an enzyme-
linked fluorescence assay (Vidas System, Biome´rieux, Marcy
l’Etoile, France) with a detection limit of 2mIU/mL.
2.7. Immunofluorescence Staining of Angiogenin in Cultured
Trophoblasts. Cell cultures (𝑛 = 5) were washed twice with
60mM Pipes/25mMHepes/10mM EGTA/2mMMgCl
2
, pH
6.9 (PHEM) at 37∘C. Cells were fixed with 4% PFA in PHEM
for 20min at room temperature. After two washes with
PHEM, remaining reactive groups were blocked by adding
50mMNH
4
Cl in PBS for 10min. Cells were washed twice in
PBS and kept in PBS at 4∘C until use. Immunofluorescence
staining was performed on cells permeabilized with 0.5%
Triton X-100 in PHEM for 2min and then washed twice
with PBS. Saturation was achieved with PBS, 10mg/mL
IgG-free BSA, 50𝜇g/mL human IgG. The monoclonal anti-
angiogenin antibody (Table 1) was diluted in the same buffer
at 6 𝜇g/mL and incubated with the cells overnight at 4∘C.
After a sequence of five washes (two with PBS, one with PBS
0.1‰ Tween 20, and two with PBS) for 2min, saturation was
achieved with PBS, 5% goat serum, 5% donkey serum for
2 h at 4∘C. The bound antibody was revealed by incubation
for 2 h at room temperature with 3.5 𝜇g/mL FITC-conjugated
goat anti-mouse IgM in PBS, 10mg/mLBSA.After a sequence
of five washes for 2min and a quick wash in distilled water,
the cells were mounted in Vectashield mounting medium
with 4󸀠,6-diamidino-2-phenylindole dihydrochloride (Dapi,
Vector Laboratories, Burlingame, CA). In negative controls,
the primary antibody was replaced by nonspecific mouse
IgM.
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2.8. Immunolocalization of Angiogenin in Human First-
Trimester Placenta and Decidua Sections. Ten-micrometer-
thick cryosections were mounted on Superfrost Plus slides
and air-dried. The sections were then either fixed and per-
meabilised (chorionic villi) or left untreated (decidua) before
immunodetection. After two washes in PBS, the sections
were fixed either with 100% acetone for 10min at −20∘C
(Figures 4(a) and 4(b)) or with 4% PFA in PBS for 20min
at 4∘C. In the case of PFA fixation, remaining free reactive
groups were blocked by adding 50mM NH
4
Cl for 10min.
After two washes in PBS, chorionic villi cryosections were
permeabilized by adding 0.5% Triton X-100 in PBS for 5min.
Following twowashes with PBS, saturationwas achievedwith
blocking buffer (PBS, 10% donkey or goat serum depending
on the secondary antibody, 50 𝜇g/mL human IgG) for 30min
at room temperature. Angiogenin was immunodetected with
either angiogenin-specific rabbit IgG or mouse IgM in block-
ing buffer overnight at 4∘C. After 6 washes in PBS for 2min,
sections were incubated with blocking buffer for 30min
and bound antibody was revealed by incubation for 1.5 h in
blocking buffer with a TRSC-conjugated donkey antibody
against rabbit IgG, FITC-conjugated goat antibody against
mouse IgM, or a TRITC-labelled goat antibody against rabbit
IgG, at room temperature. Finally, the sections were washed
six timeswith PBS and oncewith distilledwater. Cryosections
of chorionic villi were mounted in Vectashield mounting
medium with Dapi, while decidual sections were mounted
in Mowiol. Negative controls were generated by omitting
the primary antibody or by using the same concentration of
isotypic control immunoglobulin. In order to characterise the
structures exhibiting angiogenin staining, antibodies raised
against cell-type-specific markers (Table 1) were added to
the incubation medium. Bound antibodies were revealed
with FITC- or TRSC-conjugated secondary antibodies, the
choice of fluorochrome depending on the antibody used for
angiogenin detection (Table 1). The slides were examined
with an Olympus phase-contrast microscope with a fluo-
rescence attachment (BX-60). Images were captured with
a Hamamatsu C4742-95 CCD camera and VisionStage VA
software (Graftek, France). Immunolocalization studies (𝑛 =
22) were performed on cryosections from 5 placentas.
3. Results
3.1. Angiogenin Is Expressed throughout Human Placental
Development. Angiogenin transcripts were detected by RT-
PCR in placental tissues from 7.5 weeks gestation to term
(Figure 2).
3.2. Angiogenin Is Expressed by Isolated Trophoblasts In
Vitro. Extravillous cytotrophoblasts were cultured fromfirst-
trimester placentas. Angiogenin was detected with a sand-
wich ELISA in conditioned media from six of eight cultures.
The angiogenin concentration after 48 h of culture ranged
from 10 to 255 pg/mL.
Villous cytotrophoblasts were isolated and cultured from
first- and second-trimester placentas.They did not proliferate
but aggregated, fused, and formed a functional endocrine
ANG
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Figure 2: RT-PCR detection of angiogenin transcripts in human
placenta. PCR products were obtained from first-trimester placenta
RNA at weeks 7.5, 10, and 10: lanes 1, 2, and 3, respectively; from
second-trimester placenta RNA at weeks 14, 22, and 27: lanes 4, 5,
and 6, respectively; from term placenta RNA: lanes 7 and 8.
syncytium in vitro, secreting hCG as shown in Figure 3(B)(b)
[20]. Angiogenin transcripts were detected by RT-PCR in
freshly isolated trophoblasts, as well as in functional syncy-
tiotrophoblasts produced in vitro (Figure 3(A)). Angiogenin
was detected by ELISA in conditioned media through-
out the differentiation process (Figure 3(B)(a)). Angiogenin
immunostaining intensity increased with cell differentiation
(Figure 3(C)). Labelling was cytoplasmic, with marked het-
erogeneity across single, aggregated, and fused cells. Angio-
genin staining was either diffuse (more pronounced around
nuclei) or located in granules. Staining specificity was shown
by the negativity of controls (Figure 3(C)(c)).
3.3. Angiogenin Is Immunodetected In Situ in First-Trimester
Chorionic Villi. The location of angiogenin was studied by
indirect immunolocalization on cryosections of human 8-
to 9-week placentas, using two angiogenin-specific antibod-
ies: a mouse monoclonal antibody (mANG) and a rab-
bit polyclonal antibody (pANG). Schematic villus sagittal
sections and cross-sections are presented in Figures 1(b)
and 1(c). A similar labelling pattern was obtained with the
two antibodies: it covered the trophoblastic layer (identified
by cytokeratin 7 (CK7) staining) and cells located within
the villous stroma (Figure 4). Marked heterogeneity in the
labelling intensity was observed from one villous to another
and also within the villous itself (Figure 4(a)).
The trophoblastic layer was stained specifically for CK7
(Figures 4(e) and 4(f)) and was typically organised, with the
syncytiotrophoblast lying on a continuous cytotrophoblastic
layer (Figure 4(e)) in contact with the trophoblastic basement
membrane (not visible here). In some villi, the trophoblastic
layer was thinner and straightened (Figure 4(f)), as observed
in term villi. In a few places, CK7-positive cells seemed to
plunge from the trophoblastic layer into the core of the
villi (Figures 4(e) and 4(f)). The villous trophoblastic layer
was always immunolabelled for angiogenin, either uniformly
(Figure 4(c)) or more strongly in some cytotrophoblasts
(Figure 4(a)).
In the villous stroma, angiogenin was detected in some
single cells close to the trophoblastic layer (Figures 4(a), 4(c),
4(e), and 4(f), arrowhead) and also in cell masses located
deeper in the villous stroma (Figures 4(a) and 4(e)) (see
Section 3.5). No signal was observed in negative controls
(Figures 4(b) and 4(d)).
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Figure 3: Angiogenin expression by trophoblastic cells. (A) Expression of angiogenin transcripts by trophoblasts isolated from second-
trimester placenta. RT-PCR detection of a 264 bp fragment of the angiogenin transcript on 2% agarose gel stained with ethidium bromide.
Lanes 1, 3, and 5: cytotrophoblasts from 15-, 16-, and 17-week placentas prior to culture (CT0) and 2, 4, and 6: RNA from 72 h cultured
cytotrophoblasts, respectively, differentiated in vitro into a syncytiotrophoblast (ST); 7 is a negative control without RNA; 8 is a positive
control using human liver RNA. 𝛽-actin PCR gave a product at 371 bp. (B) Angiogenin release by cultured villous cytotrophoblasts from
14-week placenta. Angiogenin (ANG) was released into the culture medium during in vitro differentiation of cytotrophoblasts into a
syncytiotrophoblast (a). Human choriogonadotropin (hCG)wasmaximally expressed on day 3, indicating a functional syncytium (b). Results
are means ± SD of triplicate determinations in a representative experiment (∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗∗𝑃 < 0.0001). (C) Angiogenin
immunodetection in cultured cytotrophoblasts from first-trimester chorionic villi in vitro. The cells were fixed with paraformaldehyde and
permeabilized and then reacted with monoclonal antiangiogenin. The bound antibody was revealed with FITC-conjugated goat anti-mouse
IgM (mANG, in green). Nuclei were counterstained with Dapi (in blue). Angiogenin staining increased with cell differentiation: villous
cytotrophoblasts at day 1 (a) compared to the cells at day 2 (b); control with nonspecific mouse IgM was negative (c). Angiogenin labelling
was heterogeneous: diffuse in single cells (e, arrowhead), dense and more pronounced around nuclei in aggregating cells (b, e, and white
arrow), punctuated and associated with granules here in the syncytium (d, yellow arrow). Cells were from 13-week (a, b, and c), 12.5-week
(d), and 8.5-week (e) placenta, respectively. Bar, 20 𝜇m.
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Figure 4: Angiogenin immunoreactivity in chorionic villi from human first-trimester placentas. Frozen sections of placentas at week 8 to
9 were reacted with either a monoclonal antibody against angiogenin (a, mANG in green) or a polyclonal antibody purified by affinity on
immobilised angiogenin (c, e, f, and pANG in red). Bound antibodies were detected with fluorescent secondary antibodies. Angiogenin
immunoreactivity (pANG, in red) was detected in the trophoblastic layer immunostained for cytokeratin 7 (CK7, in green) (e, f), in some
cells in the close vicinity of the layer (arrowhead: a, in green; c, e, and f, in red) and in isolated cell masses (VCA), located deeper in the villous
stroma (a, in green; c and e, in red). The signal was stronger in some cytotrophoblasts (arrow: a). No signal was observed on cryosections
reacted with either nonspecific mouse IgM (control, b) or nonspecific rabbit IgG (control, d). Nuclei were counterstained with Dapi, in blue.
Bar, 20 𝜇m. IS: intervillous space; TB: trophoblast layer; VCA: vascular cell aggregate; and VM: villous mesenchyme.
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Figure 5: Angiogenin expression in parietal decidua: glandular epithelium and decidual cells. (A) Angiogenin immunoreactivity on frozen
sections at week 7.5, using an angiogenin-specific polyclonal antibody; the glandular epithelium showed punctuate signal corresponding to
secretory granules (a, arrowhead) and strongly delineated polyhedral decidual cells (c, arrows). No signal was observed on cryosections which
reacted with nonspecific rabbit IgG (b). (B) Angiogenin transcripts were detected in the glandular epithelium (a, arrows) and in endothelial
cells of small capillaries (a, arrowhead) on frozen sections hybridised with a digoxigenin-labelled angiogenin cDNA probe. Probe binding
was detected with an alkaline phosphatase-coupled antibody to digoxigenin and visualised with a colorimetric substrate (NBT/BCIP) (a). No
signal was observed in RNase pretreated frozen sections (b). Counterstaining with Mayer’s haematoxylin. Bar, 20𝜇m. GL, glandular lumen
and UGE, uterine glandular epithelium.
3.4. Angiogenin Is Expressed in the Decidua at Week 7.5
(Glandular Epithelium, Decidual Cells, Maternal Artery,
and Macrophages). Tissue pieces were identified as parietal
decidua based on the absence of invading cytotrophoblasts
(CK7-positive cells) and remodelled spiral arteries. Uterine
glandswere present on the cryosections (Figure 5). Glandular
epithelial cells, positive for cytokeratin (not shown), were
immunolabelled for angiogenin. The intense, punctuate sig-
nal thus obtained likely corresponded to secretory vesicles
(Figure 5A(a), arrowhead). No signal was observed in the
control (Figure 5A(b)). Angiogenin was also detected on the
outline of polyhedral decidual cells (Figure 5A(c), arrows).
Angiogenin messengers were expressed by glandular epithe-
lial cells and in endothelial cells of small maternal capillaries,
as shown by in situ hybridisation (Figure 5B(a)). No signal
was observed on negative controls either pretreated with
RNase (Figure 5B(b)) or reacting with a nonspecific probe
(not shown). The wall of spiral arteries was immunolabelled
for angiogenin (Figure 6A(a)). Specific punctuate labelling
was also observed in vimentin-positive cells (Figure 6A(a),
arrowheads).The latter cells, in close contact with spiral arter-
ies or sparser in the decidua, were shown to be macrophages,
based on theirCD14 reactivity (Figure 6A(b)).Thus,maternal
macrophages were immunolabelled for angiogenin. Angio-
genin transcripts were detected in spiral arteries by in situ
hybridisation (Figure 6B(a)). Angiogenin transcripts were
also strongly detected in unidentified small round cells.
Negative controls demonstrated the specificity of the signal
(Figure 6B(b)).
3.5. Angiogenin Expression Is Associated with First-Trimester
Chorionic Villi and Blood Vessel Formation. The structure
of the fetal vessels in the villus followed a gradient: the
least organised vessels were close to the trophoblastic layer,
while more organised ones were located deeper in the villus.
In order to identify the cells that were immunopositive for
angiogenin in developing chorionic villi, double immunola-
belling with cell markers was performed on 8-week cryosec-
tions. Besides the trophoblastic layer (Figure 4), angiogenin
staining was associated with three different structures: single
cells, cell aggregates, and cell cords (Figures 7–9). Angiogenin
labelling was associated with chorionic villi undergoing
intense morphological changes (Figure 7). The labelled cells
in close proximity of the trophoblastic layer expressed very
early endothelial markers such as VE-cadherin (Figures 7(a)
and 7(b)) and VEGF-R2 (Figures 7(c) and 7(d)). Figure 7(a)
shows a typical view of a single cell double stained for
angiogenin and VE-cadherin establishing a bridge between
cytotrophoblasts and cell aggregates (double stained), cor-
responding to a nascent fetal blood vessel. Proliferative
cells labelled for Ki-67 antigen were observed in aggre-
gates (Figure 7(e)). In less organised aggregates, Ki-67 was
present both in some trophoblastic nuclei and in nuclei
of underlying nontrophoblastic cells that were positive for
10 BioMed Research International
(a) (b)
(A)
(B)
(c)
SAL
(a) (b)
SAL SAL
GL
Figure 6: Angiogenin expression in decidua: maternal artery and macrophages. (A) Angiogenin immunoreactivity on frozen sections at
week 7.5: (a) angiogenin specific polyclonal antibody (in red) highlighted vimentin-positive cells (in green): endothelial cells of the spiral
artery (in yellow (red + green)) and sparse cells in the decidua (arrowhead). (b) Maternal macrophages (CD14 positive, in green) in a section
of 11-week placenta were immunolabelled for angiogenin (in red), compared with the isotypic negative control (c). (B) In situ hybridisation
on a frozen section of a 10-week placenta with a digoxigenin-labelled angiogenin cDNA probe revealing (in purple) angiogenin transcripts
in spiral artery, glandular epithelium, and unidentified decidual cells (a). No signal was observed in RNase pretreated frozen sections (b).
Counterstaining with Mayer’s haematoxylin. Bar, 20𝜇m. GL: glandular lumen and SAL: spiral artery lumen.
angiogenin (Figure 7(f)). Tiny cytoplasmic processes, which
are also labelled for angiogenin, were in intimate contact
with the trophoblastic layer and connected with primitive
established vessels in the core of the villi (Figures 8(a) and
8(b), arrowheads). Colabelling not only with CD31, an early
endothelial marker, but also with vWF, a later endothelial
marker, was shown in Figures 8(a) and 8(b), respectively.
These observations suggest the existence of coordinated
sites of proliferation composed of villous trophoblasts and
facing nontrophoblastic cells. In cell aggregates, double stain-
ing for angiogenin and Tie-2, an endothelial marker, was
observed (Figure 8(c)). As in term placenta, angiogenin and
erythropoietin-receptor (EpoR) labelling were colocalized in
the trophoblastic layer and in nascent or established fetal ves-
sels (Figure 8(d)).However, EpoR labelling appeared stronger
in cytotrophoblasts. In cell aggregates, colabellingwith alpha-
smooth muscle actin, a marker for vascular smooth muscle
cells and pericytes, was detected (Figure 8(e)).
Angiogenin immunolabelling was observed in cords
positive for the following early endothelial markers: VE-
cadherin, CD34, and Tie-2 or for vWF, a later vascular
marker (Figure 9). These nascent structures, corresponding
to fetal vessels in formation and previously called angioblastic
strands [23] or haemangioblastic cell cords [14], were located
in a peripheral position in the villus. CD34-positive cells
with rounded nuclei were present in these vessel segments
(Figure 9(d)) and likely corresponded to haematopoietic
precursors [24].
In the villous core, fetal macrophages (Hofbauer cells)
were immunoreactive for CD45 (Figure 8(f)) but negative
for CD14 (data not shown). The CD45-positive cells were
angiogenin-negative but lay close to angiogenin-positive
mesenchymal cells or in the close vicinity of the tro-
phoblastic layer which was labelled strongly for angiogenin
(Figure 8(f)).
In some villi, the trophoblastic layer was labelled for early
endothelial cell markers such as VE-cadherin on its basal
side (Figures 7(a) and 7(b) and Figure 9(a), arrows) and also
for VEGF-R2 (Figures 7(c) and 7(d), arrows) but not for
CD31 (Figure 8(a)), CD34 (Figure 9(d)), Tie-2 (Figure 8(c)),
or vWF (Figure 8(b)). In areas labelled for both angiogenin
and VE-cadherin, the trophoblastic layer was thickened
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Figure 7: Characterisation by double labelling of chorionic villi undergoing intense morphological changes. Frozen cross-sections of human
chorionic villi at week 8 were reacted with a mix of two primary antibodies. Angiogenin was detected with a specific polyclonal antibody
(ANG, in red). The other antibody (in green) was directed against either the early endothelial markers: VE-cadherin (a, b) and VEGF-R2 (c,
d), or the proliferation marker Ki-67 (e, f). Cells positive for the endothelial markers were stained for angiogenin. Note the angiogenin- and
VE-cadherin-positive single cell (a, arrowhead) beneath the trophoblastic layer establishing a bridge between the layer and a vascular cell
aggregate (VCA) stained for VE-cadherin; VEGF-R2-labelled VCA in close contact with the trophoblast layer (c); and angiogenin-labelled
cytoplasmic processes (d). Proliferative cells labelled for Ki-67 and angiogenin were observed in aggregates (e, green arrow). Coordinated
sites of proliferation (Ki-67+) composed of villous trophoblasts and facing nontrophoblastic cell were positive for angiogenin (f, green arrow).
White and yellow arrows point toVE-cadherin andVEGF-R2 staining of trophoblast layer, respectively. Nuclei were counterstainedwithDapi,
in blue. Bar, 20 𝜇m. IS: intervillous space; TB: trophoblast layer; VCA: vascular cell aggregate; and VM: villous mesenchyme.
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Figure 8: Immunolocalization of angiogenin in chorionic villi showing vascular cell aggregates. Frozen cross-sections of human chorionic
villi at week 8 were reacted with a mix of two primary antibodies.The bound antibodies were detected with fluorescent secondary antibodies.
The anti-angiogenin antibody was either polyclonal (a, b, e, f, and pANG in red) or monoclonal (c, d, and mANG in green). Angiogenin
colabelling with CD31 (a, in green), vWF (b, in green), Tie2 (c, in red), Epo-R (d, in red), and 𝛼-smooth muscle actin (e, sma, in green),
respectively, stained vascular cell aggregates. Arrowheads point to tiny cytoplasmic processes in close vicinity with the trophoblast layer
connected with vascular cell aggregates (a, b). Angiogenin immunoreactivity was also detected in the trophoblastic layer, in cytotrophoblasts
(also labelled for EpoR (d, in red)) and in single cells close to CD45-positive cells (f, in green, arrowhead). Nuclei were counterstained with
Dapi, in blue. Bar, 20 𝜇m. IS: intervillous space and TB: trophoblast.
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Figure 9: Angiogenin immunoreactivity in nascent vessels. Frozen sections prepared at week 8 were reacted with either a polyclonal antibody
specific for angiogenin (a, c, d, and pANG in red) or a monoclonal (b, mANG in green). The other antibody, directed against VE-cadherin
(a, in green), Tie2 (b, in red), vWF (c, in green), and CD34 (d, in green) colabelled nascent vessels. Nuclei were counterstained with Dapi, in
blue. Bar, 20 𝜇m. IS: intervillous space; TB: trophoblast layer; VCA: vascular cell aggregate; and VM: villous mesenchyme.
by superimposed nuclei (Figure 7(b)). Unlike in term villi,
the trophoblastic basement membrane of first-trimester villi
was not highlighted by angiogenin immunolabelling.
Taken together, these results show that angiogenin pro-
tein is present in the villous trophoblastic layer, structured
fetal vessels, and sites of nascent fetal vessels.
4. Discussion
Vessel formation during human placental development
occurs by means of both vasculogenesis (from in situ dif-
ferentiating endothelial cells) and angiogenesis (sprouting
of capillaries from existing vessels) [14, 25]. Fetoplacental
vasculogenesis proceeds by formation of haemangioblastic
cords which progressively linked up from day 22 to the
26th week [14, 26, 27]. Current knowledge of the cellular
and molecular mechanisms involved in human placental
blood vessel formation relies mainly on morphological and
ultrastructural observations [14, 23, 28] and immunohisto-
chemistry [27, 29, 30], but further insights are being obtained
by the study of angiogenic growth factors [10, 30–33] and
molecular methods [2].
Angiogenin has been first isolated from supernatants of
colon carcinoma cells on its property to induce angiogen-
esis in chicken chorioallantoic membrane [5]. Angiogenin
(RNase 5) belongs to the secreted RNase family, which is
vertebrate-specific and displays weak ribonucleolytic activity.
An intact catalytic site and cell-binding domain are both
required to induce neovascularization [34]. Angiogenin is
also a permissive factor for angiogenesis induced by other
angiogenic factors such as vascular endothelial growth factor
(VEGF) and fibroblast growth factor (FGF-1 and FGF-
2) [35], stimulating rRNA transcription and proliferation
[36]. Among its other properties, angiogenin promotes cell
survival, a property related to its ability to cleave tRNA and
release tiRNAs (stress-induced small RNAs), which inhibit
protein translation [37–40]. Angiogenin-induced tiRNAs
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promote stress granule assembly [37], an adaptive process
that reprograms protein translation during stress [41, 42].
In this work, in agreement with previous observations
of early placentas [30, 33, 43–45], we observed in situ
immunostaining for vessel markers on single cells in not
only close contact with the trophoblastic layer but also
deeper in the villous stroma, on cell aggregates referred to
as angioblasts by Florence Sabin in the chick [46]. Both sites
were strongly labelled for angiogenin. The current consensus
is that angioblastic cords arise from in situ differentiation
of stem cells present in the embryonic-derived mesoderm
that has invaded the chorionic villi [47]. These structures
were found here to express endothelium-specific markers at
8 weeks of gestation, namely VE-cadherin, CD31 (PECAM-
1, also present in leukocytes and platelets), VEGF-R2, Tie-
2, vWF, CD34 (also present on haematopoietic stem cells),
EpoR (also present on erythroid precursors), and angiogenin.
Some of them also expressed the smooth muscle cell marker
alpha-actin, suggesting the presence of pericytes.
Single cells in close contact with the trophoblastic layer
were found to express VE-cadherin and PECAM-1 and also
showed strong angiogenin expression.They were negative for
the trophoblast marker CK7 and for the leukocyte differenti-
ation antigens CD14 and CD45. Arthur Hertig suggested that
these single cells might derive from trophoblast delamination
and differentiation [23]. However, ultrastructural studies
showing a continuous trophoblastic basal lamina throughout
this early stage of development argue against this hypothesis
[14, 28, 48]. It might be reconsidered [49] since epithelial-
mesenchymal transitions are part of the developmental pro-
gram [50] and the human cytotrophoblastic cell has been
qualified as a “mononuclear chameleon” [51]. In certain areas,
we observed trophoblastic expression of early endothelial
markers such as VE-cadherin and VEGFR-2, as previously
described [30, 33]. A switch in cadherin expression has
been linked to cytotrophoblast differentiation [4]. However,
this epithelial-/endothelial-like conversion has been only
described for invasive cytotrophoblasts [52]. In any case, we
observed that these cells in close contact with trophoblasts
and the cellular extensions that bridge the cytotrophoblast
layer to nascent vessels expressed endothelial markers. They
were also strongly labelled for angiogenin as were the tro-
phoblasts facing them. Together, these observations point to
the existence of paracrine or juxtacrine interactions involving
angiogenin. Paracrine interaction has been shown tomediate
angiogenin neuroprotection. Skorupa et al. [53] have shown
that angiogenin secreted by motoneurons is endocytosed
by astroglia via syndecan 4. Interestingly, the paracrine
RNA fragments in astrocytes differ from those previously
described but their biological function is unknown. These
observations from studies of the nervous system highlight the
fundamental properties of angiogenin.
Angiogenin immunolabelling in early chorionic villi was
associated with actively dividing endothelial and trophoblas-
tic cells, possibly reflecting coordinatedmorphological devel-
opment. In early placenta, vasculogenesismight be controlled
by villous cytotrophoblast [30]. In this work, angiogenin
was expressed by cytotrophoblasts. The fact that angiogenin
binds to endothelial cells via high affinity binding sites [54]
and stimulates proliferation [55, 56] and differentiation in
vitro [57] suggests that cytotrophoblasts might release angio-
genin as a paracrine signal to endothelial cells. Reciprocally
endothelial cells might signal to trophoblastic cells in early
villus development. It has been shown in developing organs
such as liver, pancreas, or prostate that early endothelial
cells and nascent vascular structures provide developmental
signals to the growing organ throughout its development,
even prior to blood vessel formation [58, 59]. In this
work, angiogenin expression observed in situ corroborates
its expression by endothelial cells in vitro [60]. However,
evidence for angiogenin receptor on cytotrophoblasts is not
yet documented. Taken together, these observations suggest
cooperation between villous trophoblasts and nascent fetal
blood vessels.
Unlike term placenta, the villous tree in first-trimester
placenta (up to 10–12 weeks of gestation) does not bathe in
maternal blood but in an exudate. Indeed, maternal spiral
arteries are obstructed by intra-arterial cytotrophoblastic
plugs, which block the entry of maternal blood into the
intervillous space throughout the first trimester. The epithe-
lium of endometrial glands is known to secrete material that
is discharged into the lumen (uterine milk) [61, 62]. These
secretions, a source of growth factors such as epidermal
growth factor (EGF), VEGF, and leukaemia inhibitory factor,
are delivered to the placental intervillous space. Fetal nutri-
tion may thus be histiotrophic during this period [63, 64].
Angiogenin is a secreted protein present in amniotic fluid
[65], follicular fluid [66], and plasma [67]. The punctuate
angiogenin immunostaining of glandular epithelial cells from
7.5-week decidua points to the presence of secretory vesicles.
At this time, the oxygen tension is <20mmHg [63]. Low but
physiological oxygen tensionmay stimulate villous sprouting
and capillary growth [15]. Angiogenin expression has been
shown to be upregulated by hypoxic conditions in cultured
cells, including granulosa cells [66], decidual cells [68], chori-
ocarcinoma cells, and Simian virus 40 transformed placental
cells [69]. Angiogenin might participate, along with other
cytokines such as EGF, VEGF, and tumor necrosis factor-𝛼,
in regulating trophoblast proliferation and/or migration and
might influence the remodelling of uteroplacental arteries.
Angiogenin was also expressed in decidual cells from
first-trimester placenta, where it was strongly associated with
the matrix which reminds that angiogenin is a heparin-
binding protein [70] that binds to the extracellular matrix
[54]. It has been shown that angiogenin is present in placental
stromal and epithelial cells, with increased expression in
the endometrium in the mid- and late secretory phases
and early gestation [68]. In the decidua, we found that the
uterine arteries and surrounding maternal macrophages also
expressed angiogenin.The decidual environment is known to
be immunosuppressive [71]. Angiogenin has been reported to
function as an immunomodulator [72–74]. It is conceivable
that angiogenin could thus participate in maternal immune
tolerance towards the semiallogenic fetus.
Based on the other known biological activities of angio-
genin and on its pattern of placental expression, our findings
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suggest that angiogenin, in concert with other regulators,may
play a fundamental role in placental organogenesis.
5. Conclusions
This work shows that angiogenin is expressed through-
out human placental development. In the early placenta,
angiogenin is expressed by extravillous and villous cytotro-
phoblasts, as well as by functional syncytiotrophoblasts
differentiated in vitro. A compatible pattern of angiogenin
expression was observed in situ. Angiogenin expression in
extravillous cytotrophoblasts in vitro and in the maternal
decidua in situ (uterine glands, decidual cells, maternal
artery and small capillaries, and macrophages) suggests that
angiogenin may play a role in the decidual environment.
The cellular pattern of angiogenin distribution in early first-
trimester mesenchymal villi suggests a role in blood vessel
formation. Fine analysis with cell-type-specific markers sug-
gests a role of angiogenin in cross-talk between trophoblasts
and endothelial cells. In view of its known biological activi-
ties, our findings suggest a fundamental role of angiogenin in
early placental development.
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